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Mock IRB 
Washington University in St. Louis 
October 30, 2013 
1 
Live Stream 
Click this link  or copy link to your browser to 
view the Mock IRB.  
http://stream.nts.wustl.edu/R131029001/ 
 
Slides for the Mock IRB follow. 
2 
CNE Disclosures 
 Successful Completion: Participants must complete an evaluation form to 
receive a certificate of completion 
 Contact Hours: 1 contact hour is available to those who meet the successful 
completion requirements 
 Sponsorship & Commercial Support: This activity has received no 
sponsorship or commercial support 
 Conflict of Interest: No conflicts of interest were identified 
 Non-Endorsement: Accreditation approval refers only to MONAs continuing 
education activities and does not imply MONA or ANCC Commission on 
Accreditation endorsement of any commercial products 
 Off Label Use: There will be no discussion of uses of products other than 
what is approved by the FDA. 
 Expiration: Contact Hours expire on October 29, 2015 
 
3 
Titles in Human Subjects Research 
• FDA: 21 CFR 50 and 56 
• HHS: 45 CFR 46 
4 
• Risks to subjects are minimized 
• Risks to subjects are reasonable in relation to 
anticipated benefits 
• Selection of subjects is equitable 
• Obtain informed consent 
• Document informed consent 
• Monitoring plan 
• Protect privacy & maintain confidentiality 
• Protect vulnerable populations 
 
Criteria for approval 45 CFR 46.111, 21 CFR 56.111 
5 
Actors and their Role 
 Principal Investigator (PI) Suresh Vedantham 
 IRB Chair Ed Casabar 
 IRB Administrative Rep. Michael Leary  
 IRB Analyst  Linda VanZandt 
 IRB Coordinator Charmin Montgomery 
 Physician Scientist (PS)  Mitchell Sommers 
 Other Scientist (OS1) Michelle Jenkerson 
 Other Scientist (OS2) Sarah Fowler-Dixon 
 Non-Scientist (NS) Niki Bridges 
  
 Narrator, Martha Jones 
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Reviewers’ Responsibilities 
• All committee members are responsible for 
reviewing all agenda items prior to the 
meeting so they can discuss and vote on all 
items. 
7 
Study Documents sent for IRB Review 
and Approval Attachments 
Study Materials 
• Study Protocol 
• Grant 
• Investigator’s Brochure 
• FDA IND approval letter 
• Adult consent form 
• Minor assent form 
• Spanish adult consent form 
• Spanish minor assent form 
• Translation certification 
• Phone scripts 




• Facebook advertisement 
• Social media discussion 
boards used for recruitment 
• Study website  
• Physician poster 
• Subject poster 
• Patient brochure 




The purpose of this study 
• To determine if Pharmacomechanical CDT (PCDT) 
should be routinely used to treat proximal DVT. In 
order to do this, they are conducting a 
multicenter randomized clinical trial (the Acute 
Venous Thrombosis: Thrombus Removal with 
Adjunctive Catheter-Directed Thrombolysis 
[ATTRACT] Trial) to establish whether PCDT 
prevents Post-Thrombotic Syndrome (PTS) and 
improves health-related Quality of Life (QOL) with 
acceptable safety and costs.  
9 
The Primary Objective  
• To determine if initial adjunctive use of PCDT 
(using rt-PA) with optimal standard DVT 
therapy reduces the occurrence of the Post-
Thrombotic Syndrome during 24 months of 
follow-up compared with optimal standard 
DVT therapy alone. 
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•  (1) Risks to subjects are minimized:  
– (i) By using procedures which are consistent with sound research 
design and which do not unnecessarily expose subjects to risk, 
and  
– (ii) whenever appropriate, by using procedures already being 
performed on the subjects for diagnostic or treatment purposes. 
 
•  (2) Risks to subjects are reasonable in relation to anticipated 
benefits, if any, to subjects, and the importance of the 
knowledge that may reasonably be expected to result.  
– In evaluating risks and benefits, the IRB should consider only 
those risks and benefits that may result from the research (as 
distinguished from risks and benefits of therapies subjects would 
receive even if not participating in the research).  
– The IRB should not consider possible long-range effects of 
applying knowledge gained in the research (for example, the 
possible effects of the research on public policy) as among those 
research risks that fall within the purview of its responsibility 
 
Regulatory Criteria for Approval 
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Children: Research must fit into one of the following categories 
 • 45 CFR 404; 21 CFR 50.51- Research not involving greater than minimal 
risk. 
– Minimal Risk means that the probability and magnitude of harm 
or discomfort anticipated in the research are not greater in and 
of themselves than those ordinarily encountered in daily life or 
during the performance of routine physical or psychological 
examinations or tests. 
– Adequate provisions are made for soliciting the assent of the 
children and permission of their parents or guardians 
 
• 45 CFR 405; 21 CFR 50.52- Research involving greater than minimal risk but 
presenting the prospect of direct benefit to the individual subjects. 
– (a) The risk is justified by the anticipated benefit to the subjects; 
– (b) The relation of the anticipated benefit to the risk is at least as 
favorable to the subjects as that presented by available 
alternative approaches; and 
– (c) Adequate provisions are made for soliciting the assent of the 
children and permission of their parents or guardians 
 
12 
Children: Research must fit into one of the following categories 
• 45 CFR 406; 21 CFR 50.53- Research involving greater than minimal 
risk and no prospect of direct benefit to individual subjects, 
but likely to yield generalizable knowledge about the 
subject's disorder or condition. 
– (a) The risk represents a minor increase over minimal risk; 
– (b) The intervention or procedure presents experiences to 
subjects that are reasonably commensurate with those 
inherent in their actual or expected medical, dental, 
psychological, social, or educational situations; 
– (c) The intervention or procedure is likely to yield 
generalizable knowledge about the subjects' disorder or 
condition which is of vital importance for the 
understanding or amelioration of the subjects' disorder or 
condition; and 
– (d) Adequate provisions are made for soliciting assent of 
the children and permission of their parents or guardians 
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Children: Research must fit into one of the following categories 
• 45 CFR 407; 21 CFR 50.54-  Research not otherwise approvable 
which presents an opportunity to understand, prevent, or 
alleviate a serious problem affecting the health or welfare of 
children 
– Research in this category must be reviewed by the IRB 
which determines that it does not fall into one of the 
previous categories 
– The study with the IRB findings is then submitted to the 
DHHS Secretary/FDA Commissioner for review by a panel 




















Minimal N/A 404 1 
Medical History Minimal N/A 404 1 
Physical Exam Minimal N/A 404 1 
Review of diagnosis 
of qualifying DVT 
episode 
Minimal N/A 404 1 
Lab assessment Minimal  N/A 404 1 
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Component analysis: Pre-Screen 
















Questionnaires Minimal N/A 404 1 
Calf 
circumference 
Minimal N/A 404 1 
Villalta PTS scale Minimal N/A 404 1 
Venus duplex 
ultrasound 





Minimal  N/A 404 1 
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Component analysis: Study Procedures 





























Final Risks to Minors Based on Component Analysis 
Risk Rating  Requirements 
404; 51 
Minimal 
One parent’s consent 
(One or two may be required by IRB) 
405; 52  
> Minimal, Direct benefit 
  
One parent’s consent 
(One or two may be required by IRB) 
Risk justified by anticipated direct benefit 
Benefit approximate to alternatives’ benefit 
406; 53  
> Minimal, No direct benefit 
Both parents’ consent 
 Minor risk over minimal 
 Children must have disease/condition under study 
No direct benefit 
407; 54  
Not otherwise approvable 
Both parents’ consent 
Generalizeable knowledge 
Additional approval from DHHS/FDA 
18 
Criteria for approval of Research  
• (4) Informed consent will be sought from each 
prospective subject or the subject's legally 
authorized representative, in accordance with, 
and to the extent required by §46.116. 
 
•  (5) Informed consent will be appropriately 
documented, in accordance with, and to the 
extent required by §46.117. 
 
19 
Criteria for approval 45 CFR 46.111, 21 CFR 56.111 
• (3) Selection of subjects is equitable. In 
making this assessment the IRB should take 
into account the purposes of the research and 
the setting in which the research will be 
conducted and should be particularly 
cognizant of the special problems of research 
involving vulnerable populations, such as 
children, prisoners, pregnant women, mentally 
disabled persons, or economically or 
educationally disadvantaged persons. 
 20 
Criteria for approval of Research  
 
• (6) When appropriate, the research plan 
makes adequate provision for monitoring the 
data collected to ensure the safety of subjects. 
 
21 
Criteria for approval of Research  
• (7) Adequate provisions to protect the privacy 
of subjects and to maintain the confidentiality 
of data:  
22 
Privacy and Confidentiality Definitions 
• Privacy: The freedom of the individual to pick 
and choose for him/herself the time and 
circumstances under which, and to the extent 
to which his/her attitudes, beliefs, behavior 
and opinions are to be shared with or withheld 
from others. (Levine, p 163) 
 
• Confidentiality: Mode of management of 
private information. (Levine, p. 163) 
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Criteria for approval of Research  
• (7) (b) When some or all of the subjects are 
likely to be vulnerable to coercion or undue 
influence, such as children, prisoners, 
pregnant women, mentally disabled persons, 
or economically or educationally 
disadvantaged persons, additional safeguards 
have been included in the study to protect the 
rights and welfare of these subjects. 
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Do you have a blood clot in your leg (DVT)? 
In this National Institutes of Health sponsored study, all patients will receive blood-thinning drugs, the standard treatment 
for blood clots. In addition, half of all study patients will be chosen to have their clot dissolved using a new treatment that a 
doctor will inject directly into the clotted vein through a specifically –designed drug delivery catheter.  The other half of the 
patients will receive standard medical care. 
 
Consider joining the ATTRACT study.  
All patients will be followed for two years by a specialized team of doctors and nurses to determine if the new clot-
busting treatment (TPA) helped prevent long-term complications such as pain, swelling, or skin ulcers (open sores) of 
the leg.  
 
 
Eligible participants must be between the ages of 16 and 75. 
Each person will be paid $1000. 
Please call. 
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Do you have a blood clot in your leg (DVT)? 
In this National Institutes of Health sponsored study, all patients will receive blood-thinning drugs, the standard treatment 
for blood clots. In addition, half of all study patients will be chosen to have their clot dissolved using a                             
that a doctor will inject directly into the clotted vein through a specifically –designed drug delivery catheter.  The other half 
of the patients will receive standard medical care. 
 
Consider joining the ATTRACT study.  
All patients will be followed for two years by a specialized team of doctors and nurses to determine if the new clot-
busting treatment (TPA) helped prevent long-term complications such as pain, swelling, or skin ulcers (open sores) of 
the leg.  
 
Eligible participants must be between the ages of 16 and 75. 
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new treatment  
Each person will be paid $1000. 
Please Call. 
Sponsor-Investigator Responsibility 
• 21 CFR 312.50 Subpart D--Responsibilities of Sponsors and 
Investigators 
 






• WU Investigational Drug/Device Accountability 
http://research.wustl.edu/PoliciesGuidelines/Pages/IDDA.aspx 
 
• WU IND Awareness Training for Sponsor-Investigators 
– Contact HRPO at 314-633-7400 
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Coordinating Center or Lead Site should: 
• Have written agreements with their sites  
• Ensure IRB approvals are obtained at all sites 
• Ensure proper training and qualifications 
• Should develop standard operating procedures 
• Ensure monitoring for all sites 
• Collect all adverse events study-wide for data 
safety monitoring 
• Have regular communications with all sites 
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Final Determinations 
• Prescriptive Changes to the consent and myIRB application, 
and the recruitment advertisement 
 
• Adults: Greater than Minimal Risk 
 
• Minors: Both 45 CFR 404 and 405; 21 CFR 50.51 and 50.52 
– One parent signature 
– Assent process is appropriate with the prescriptive change to allow the 
child to discuss the study privately with the research team 
 
• Continuing review in 1 year 
29 
Thank you 
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